Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum

Annals of Surgical Oncology

Volumn 14, Issue 12, 2007, Pages 3460-3471

  Varghese, Sheelu ^a   Burness, Monika ^b   Xu, Hui ^b   Beresnev, Tatiana ^b   Pingpank, James ^b   Alexander, H Richard ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Colorectal cancer; GI adenocarcinoma; Metastases; Microarray

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE REGULATION; CELL PROLIFERATION; CLUSTER ANALYSIS; COLORECTAL ADENOMA; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GASTROINTESTINAL CARCINOMA; GENE CONTROL; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE ISOLATION; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PERITONEUM METASTASIS; PROTO ONCOGENE; SEGREGATION ANALYSIS; SITE DIRECTED MUTAGENESIS; UPREGULATION;

ADENOCARCINOMA; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PERITONEAL NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 36349021340     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9557-7     Document Type: Article

References (27)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2(9):533-43
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2):106-30
3. Ballantyne GH, Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 1993; 71(12 Suppl):4252-66
4. Kim J, Takeuchi H, Lam ST, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005; 23(12):2744-53
5. Smakman N, van der Bilt JD, van den Wollenberg DJ, et al. Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther 2006; 13(8):815-8
6. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88(2):358-63
7. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006; 7(1):69-76
8. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995; 221(2):124-32
9. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22(2):229-37
10. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343(13):905-14
11. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22(16):3284-92
12. Culliford AT, Brooks AD, Sharma S, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 2001; 8(10):787-95
13. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40(3):667-76
14. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of roigin, prognosis, and relationship to "pseudomyxoma peritonei." Am J Surg Pathol 1995; 19(12):1390-408
15. Alexander HR Jr, Weinreich DM. Treatment of unresectable cancers confined to liver using vascular isolation and perfusion. In: DeVita VT, Hellman S, Rosenberg SA (eds.) Updates; Principles and Practice of Oncology, Philadelphia, PA: Lippincott Williams & Wilkins, 2001:1-16
16. Alexander HR, Bartlett DL, Libutti SK. National Cancer Institute experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity. In: Markman M (ed.) Current Clinical Oncology: Regional Chemotherapy: Clinical Research and Practice, Totowa, NJ: Humana Press, 1999:127-50
17. Brown DM, Ruoslahti E. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 2004; 5(4):365-74
18. van 't Veer LH, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415(6871):530-36
19. Takamura M, Ichida T, Matsuda Y, et al. Reduced expression of liver-intestine cadherin is associated with progression and lymph node metastasis of human colorectal carcinoma. Cancer Lett 2004; 212(2):253-9
20. Hippo Y, Taniguchi H, Tsutsumi S, et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 2002; 62(1):233-40
21. Hinoi T, Lucas PC, Kuick R, et al. CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology 2002; 123(5):1565-77
22. Lyall MS, Dundas SR, Curran S, et al. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 2006; 12(4):1184-91
23. Curran S, Dundas SR, Buxton J, et al. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004; 10(24):8229-34
24. Holten-Andersen MN, Stephens RW, Nielsen HJ, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000; 6(11):4292-9
25. Holten-Andersen MN, Nielsen HJ, Sorensen S, et al. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Eur J Cancer 2006; 42(12):1889-96
26. Nosho K, Yamamoto H, Adachi Y, et al. Gene expression profiling of colorectal adenomas and early invasive carcinomas by cDNA array analysis. Br J Cancer 2005; 92(7):1193-200
27. Diao A, Rahman D, Pappin DJ, et al. The coiled-coil membrane protein golgin-84 is a novel rab effector required for Golgi ribbon formation. J Cell Biol 2003; 160(2):201-12